# Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

Source: https://onco.cc/trials/nct06225843/  
OnCo record `nct06225843` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FOLFOX in colorectal cancer, run by Alethia Biotherapeutics, now recruiting.

## Summary

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis is a phase 2 interventional study registered as NCT06225843 by Alethia Biotherapeutics, with 17 participants planned, started 2024-02-15 and due to reach its primary completion in 2026-03. Interventions recorded: Sotevtamab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06225843
- Phase: 2
- Setting: A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
- Sponsor: Alethia Biotherapeutics
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT06225843: https://clinicaltrials.gov/study/NCT06225843

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Sotevtamab](https://onco.cc/drugs/sotevtamab/)

---
JSON: https://onco.cc/api/v1/entities/nct06225843.json